The present invention concerns CAR CAR T and CAR NK constructs preferably comprising a scFv antibody fragment against a disease associated antigen or a hapten. More preferably the antigen is a TAA such as Trop 2. The constructs may be administered to a subject with a disease such as cancer autoimmune disease or immune dysfunction disease to induce an immune response against disease associated cells. Where the constructs bind to a hapten the subject is first treated with a hapten conjugated antibody that binds to a disease associated antigen. Therapy may be supplemented by other treatments such as debulking procedures (e.g. surgery chemotherapy radiation therapy) or coadministration of other agents. More preferably administration of the construct is preceded by predosing with an unconjugated antibody that binds to the same disease associated antigen. Most preferably an antibody against CD74 or HLA DR is administered to reduce systemic immunotoxicity induced by the constructs.
